May 9, 2025
The article describes our lab’s clinical trial, GIANT, which seeks to evaluate a novel neoadjuvant immunotherapy approach for glioblastoma, one of the most lethal brain cancers. The study will test a combination of nivolumab and relatlimab, immune checkpoint inhibitors previously used for melanoma, to see if they can improve outcomes when administered before surgery in newly diagnosed patients.
As the U.S. principal investigator and study chair, Dr. Khasraw is overseeing trial design, treatment implementation, and tumor analysis at Duke, while leading a U.S.-Australia research consortium to evaluate the therapy’s biological impact using cutting-edge spatial technologies. His leadership in integrating immunotherapy into earlier treatment phases aims to transform how glioblastoma is managed and unlock new insights into tumor immune response.
Read the full article here.